Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis
Kai Zhang,* Ruoxi Hong,* Fei Xu, Wen Xia, Lee Kaping, Ge Qin, Qiufan Zheng, Qianyi Lu, Yan Xia Shi, Zhong Yu Yuan, Shusen Wang Sun Yat-Sen University Cancer Center, The State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People&...
Main Authors: | Zhang K, Hong R, Xu F, Xia W, Kaping L, Qin G, Zheng Q, Lu Q, Shi YX, Yuan ZY, Wang SS |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-08-01
|
Series: | Cancer Management and Research |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-value-of-circulating-esr1-mutations-for-patients-with-metasta-peer-reviewed-article-CMAR |
Similar Items
-
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer
by: Florian Clatot, et al.
Published: (2020-05-01) -
Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients
by: Nick Beije, et al.
Published: (2018-01-01) -
Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
by: Takashi Takeshita, et al.
Published: (2017-11-01) -
Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients
by: Violette Allouchery, et al.
Published: (2018-05-01) -
<i>ESR1</i> NAPA Assay: Development and Analytical Validation of a Highly Sensitive and Specific Blood-Based Assay for the Detection of <i>ESR1</i> Mutations in Liquid Biopsies
by: Dimitra Stergiopoulou, et al.
Published: (2021-02-01)